Sentinel lymph node biopsy (SLNB) is a well-established procedure for staging clinically node-negative early breast cancer (BC). Superparamagnetic iron oxide (SPIO) demonstrated efficacy for nodal identification using a magnetic probe after local retroaeroal interstitial injection. Its benefits lie in its flexibility, which is an essential property in the global setting, where access to the isotope is difficult. To the best of our knowledge, this is the first study to evaluate the feasibility and safety of the SPIO for SLNB in BC patients treated with neoadjuvant chemotherapy (NAC). Seventy-four female patients were included. The median time of lymph node retrieval was 20 min. The median number of resected sentinel nodes (SNs) was 4. SN was detected in all patients. No serious adverse event was observed. SPIO in identifying SN in BC patients after NAC is feasible and oncologically safe.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8305632PMC
http://dx.doi.org/10.3390/jcm10143149DOI Listing

Publication Analysis

Top Keywords

lymph node
12
superparamagnetic iron
8
iron oxide
8
sentinel lymph
8
breast cancer
8
neoadjuvant chemotherapy
8
oxide identifying
4
identifying sentinel
4
node breast
4
cancer neoadjuvant
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!